Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Maha Hussain, M.D., Joaquin Mateo, M.D., Karim Fizazi, M.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Antoine Thiery-Vuillemin, M.D., Przemyslaw Twardowski, M.D., et al., for the PROfound Trial Investigators*

Click here to read more.

Interview with Dr. Neal Shore Featured on WCSC Live 5 News

Prostate cancer treatment interview with Dr. Neal Shore featured on WCSC Live 5 News

Click on the video below to watch the interview:

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Karim Fizazi, M.D., Neal Shore, M.D., Teuvo L. Tammela, M.D., Ph.D., Albertas Ulys, M.D., Egils Vjaters, M.D., Sergey Polyakov, M.D., Mindaugas Jievaltas, M.D., Murilo Luz, M.D., Boris Alekseev, M.D., Iris Kuss, M.D., Marie-Aude Le Berre, M.Sc., Oana Petrenciuc, M.D., et al., for the ARAMIS Investigators*

Click here to read more.

CURC & Dr. Neal Shore Featured In USA TODAY Article On FDA Approval of Liquid Biopsy Testing

‘Coming into their own’: FDA approval of liquid biopsy tests puts early, less invasive cancer detection in broader reach

Click here to read more.

CURC is 1st clinic in USA to include a patient in treatment in RhoVac’s clinical phase IIb study

First patient in treatment in RhoVac’s clinical phase IIb study in the USA

Click here to read more.

Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer

Speaker: N. Shore, Myrtle Beach (US)   Event: 35th Annual EAU Congress – Virtual (EAU20V)
 

Dr. Shore joins the Duke Global Health Institute Board of Advisors

Dr. Neal D. Shore has been invited to join the prestigious Duke Global Health Institute Board of Advisors

The inaugural board of advisors for Duke Global Health Institute, founded in 2009, was composed of 14 visionary members who embraced Duke’s vision to build a world-class program that would lead its peers in the charge to address global health disparities. The work of that group played a vital role in developing DGHI into the establishment it is today, with over 400 students and 100 faculty from 8 Duke schools, conducting research in over 40 countries.

The DGHI board of advisors is entering its own phase of growth, from 15 to 25 members over the next five years. DGHI values board service and seeks to: 1) cultivate members’ interest in global health by providing opportunities for learning, meaningful discourse and interaction with leaders in the field; 2) honor its members’ contribution of time and effort by enlisting guidance and expertise on matters for which they can be most impactful; 3) foster in its members a sense of inspiration and purpose by facilitating interaction with students, faculty and staff; and 4) create an experience that deepens members’ affinity and connection to Duke University.

In creating a positive and engaging board experience, DGHI aims to empower its advisory board members to serve in a variety of ways: as thought partners, champions, investors and ambassadors who facilitate relationships and opportunities that support its mission. The DGHI advisory board convenes twice annually, once in the spring and another in the fall. Spring meetings rotate between New York, NY and Washington, DC; and fall meetings meet in Durham, NC. Terms of service last three years, and are renewable once by mutual agreement.

Dr. Shore’s educational and professional background, philanthropic investments, and alumnus status made him a fortuitous addition.

Click here to read more about The Duke Global Health Institute.

Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer

Presented by: Neal D. Shore, Paul F. Schellhammer, Ronald F. Tutrone, Neil F. Mariados, Stacey S. Harrelson

Click here to read more.

Olaparib for Metastatic Castration-Resistant Prostate Cancer- Published in The NEW ENGLAND JOURNAL of MEDICINE

Johann de Bono, M.B., Ch.B., Ph.D., Joaquin Mateo, M.D., Ph.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal Shore, M.D., Shahneen Sandhu, M.D., Kim N. Chi, M.D., Oliver Sartor, M.D., Neeraj Agarwal, M.D., David Olmos, M.D., Ph.D., Antoine Thiery-Vuillemin, M.D., Ph.D., Przemyslaw Twardowski, M.D., et al.

Click here to read more.

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer- Published in The NEW ENGLAND JOURNAL of MEDICINE

Neal D. Shore, M.D., Fred Saad, M.D., Michael S. Cookson, M.D., M.M.H.C., Daniel J. George, M.D., Daniel R. Saltzstein, M.D., Ronald Tutrone, M.D., Hideyuki Akaza, M.D., Alberto Bossi, M.D., David F. van Veenhuyzen, M.B., Ch.B., M.Pharm.Med., Bryan Selby, M.S., Xiaolin Fan, Ph.D., Vicky Kang, M.D., et al., for the HERO Study Investigators*

Click here to read more.